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Renal-coloboma syndrome, also known as papillorenal syndrome, is an autosomal dominant human disorder
in which optic disc coloboma is associated with kidney abnormalities. Mutations in the paired domain tran-
scription factor PAX2 have been found to be the underlying cause of this disease. Disease severity varies
between patients, and in some cases, renal hypoplasia has been found in the absence of any retinal defects.
Here we report an N-ethyl-N-nitrosourea-induced mouse mutation, Opdc, which is an isoleucine to threonine
missense mutation, I40T, in the first a-helix of the Pax2 paired domain. The mutant protein binds target DNA
sequences less strongly than the wild-type protein and acts poorly to transactivate target promoters in cul-
ture. The phenotypic consequence of this mutation on the development of the eye and ear is similar to that
reported for null alleles of Pax2. However, in homozygotes, cerebellar development is normal on a genetic
background in which loss of Pax2 results in failure of cerebellar formation. Moreover, there is a genetic back-
ground effect on the heterozygous phenotype such that on some strain backgrounds, kidney development is
unaffected. Opdc is the first hypomorphic mutation reported for Pax2 that differs in phenotype from loss-of-
function mutations. These results suggest that PAX2 is a strong candidate gene for cases in which human
patients have optic disc coloboma not associated with renal dysplasia.
INTRODUCTION
Papillorenal syndrome (OMIM 120330, also known as renal-
coloboma syndrome or RCS) is an autosomal dominant
human disease in which abnormalities of the optic disc and
retina are associated with renal malformations and vesicouret-
eral reflux (1). In many cases, mutations of the transcription
factor PAX2 have been found to be associated with the
disease (2). The disease severity varies even within families,
and in some cases, kidney defects can manifest without the
associated eye disorder (3,4). In addition, hearing loss is part
of the syndrome in some families (3), and there has been a
rare case described in which Chiari 1 malformation of the cer-
ebellum was found in a patient with eye and renal defects
associated with a PAX2 mutation (5). Pax2 is a member of
the PAX family of transcription factors that all contain the
paired domain, a conserved 128 amino acid DNA-binding
domain (6,7). This domain has a bipartite structure consisting
of two structurally independent globular subdomains, each
containing three a-helices connected by a linker region.
Both subdomains bind to specific DNA sequence motifs in
recognition sites enabling PAX2 to control the expression of
target genes (8,9). The importance of the two subdomains in
binding site recognition is not equivalent however; the N-
terminal subdomain makes a more significant contribution to
DNA binding than the C-terminal subdomain (8,10,11).
Almost all of the PAX2 mutations that have been found are
predicted to be loss of function as they are termination,
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splice site mutations or insertions and deletions of variable
length (reviewed in 12). Only two missense mutations have
been found to be associated with RCS, both in the N-terminal
subdomain of the paired domain (13,14). The G76S mutation
is located immediately after the third a-helix of this subdo-
main and is thought to disrupt protein folding (13). Structural
studies on the PAX6 paired domain show that the small side
chain of the equivalent glycine residue is important to pack
against the side chain of a tyrosine residue in the hydrophobic
core of the N-terminal subdomain (11). The R71T mutation is
found close by within the third a-helix of the N-terminal sub-
domain, which is the sequence recognition helix and fits into
the major groove of the DNA (14). The equivalent arginine
residues in the paired domains of Drosophila prd and human
PAX6 proteins directly interact with the DNA recognition
sequence (9,11). Substitution of arginine by threonine presum-
ably disrupts target site recognition, although this has not been
investigated.
Several mouse models of PAX2 disease have been engin-
eered or identified. Two Pax2 mutations have been found to
date by screening mice for phenotypic variation. Interestingly,
the mutations are very similar to ones already described in
humans and produce similar defects. The Pax21Neu allele is
an insertion of a single G, expanding a tract of seven Gs to
eight (15). This is identical to the mutation in a severely
affected patient with cerebellar, in addition to eye and
kidney, defects (16). Another recently reported mutation,
found by screening mutagenized mice, results in a threonine
to alanine substitution at codon 74 (T74A) (17). This is the
final amino acid of the third a-helix of the N-terminal subdo-
main of the paired domain and is equivalent to T75 in the
human protein. It is located immediately before the position
of the human missense mutation G76S described earlier and
is part of a two-amino-acid duplication in a human patient
with RCS (13). All mouse mutations, including the T74A mis-
sense mutation, have very similar heterozygous phenotypes,
which model the human disorder, comprising dysplasia of
the optic disc and associated retinal and vascular defects,
occasional unilaterally absent kidneys and frequent small or
polycystic kidneys. The mouse models allow investigation of
the homozygous phenotype, which further illuminates the
role of Pax2 in development. Mice homozygous for loss of
the gene fail to develop kidneys, die at birth and have colobo-
mas due to the failure of the optic fissure to close (18,19). In
addition, the mutants have an absence of cochlea in the inner
ear and additional brain defects (19). Genetic background
modulates the effects of loss of function of Pax2 on brain
development. Pax2 mutants on the C3H genetic background
lack a cerebellum and parts of the hindbrain (15), whereas
on the C57BL/6 genetic background, this defect is not seen
(20). Exencephaly occurs in 100% of Pax2-deficient
embryos on the 129SvPas (129S2) genetic background,
whereas on the C57BL/6 background, the frequency drops to
30% (20). We describe here the identification of a Pax2
mutation in the Opdc mutant line. The phenotype of heterozy-
gous mice is milder than described for loss-of-function
mutations. Consistent with this, the mutant protein is still
able to bind to Pax2 target sequences, albeit at lower affinity,
and retains the ability to stimulate transcription from some
promoters. In addition, the expression levels of downstream
target genes we tested are not significantly affected in hetero-
zygotes.
RESULTS
Opdc is a point mutation in the Pax2 gene
We identified the N-ethyl-N-nitrosourea (ENU)-induced
mouse mutation, optic disc coloboma (Opdc), in a screen for
dominant eye mutations. Mice that carry Opdc have bilateral
colobomas of the optic disc (21). We previously mapped
Opdc between the markers D19Mit46 and D19Mit103 on
chromosome 19 (21). Within this interval, the paired box con-
taining transcription factor, Pax2, is a strong candidate for the
Opdc mutation because of the similarity between the retinal
phenotype observed in Opdc heterozygotes and in mice het-
erozygous for known mutant alleles of Pax2, such as the spon-
taneous mutation Pax21Neu (15) and the targeted alleles, for
example, Pax2tm1Pgr (18). We amplified by polymerase
chain reaction (PCR) and sequenced the exons of Pax2 and
their flanking regions from Opdc mutant mice, the parental
strain BALB/cAnN and the two strains used to map and main-
tain the mutation, C3H/HeH and C57BL/6. We found a single
nucleotide change, a T-to-C transition in exon 2 at position
119 (numbering from RefSeq entry NM_011037.3), in the
Opdc allele absent from the three background strains
(Fig. 1A). This causes a non-conservative missense mutation,
I40T, exchanging the hydrophobic amino acid isoleucine for
the nucleophilic and hydrophilic amino acid threonine. The
affected isoleucine is located in the first a-helix of the N-
terminal subdomain of the DNA-binding paired domain and
is conserved both among other members of the PAX family
of transcription factors and across species (Fig. 1B). In spite
of the non-conservative nature of the amino acid substitution
induced by the mutation, secondary structure prediction
using the program JPRED suggests that the I40T mutation
would not disrupt the helical structure of this helix (data not
shown). Although I40 is in the paired domain, its position in
the three-dimensional (3D) model structure suggests that it
does not directly contact DNA (Fig. 1C). The structure of
the paired domain of the closely related proteins PAX6 and
PAX5 bound to their DNA recognition sites has been deter-
mined (11,22). The equivalent isoleucine in these structures
is in the first a-helix, remote from the DNA recognition
sequence and not in a position where it can directly contact
DNA (Fig. 1C). Sequencing of Pax2 reverse transcription
(RT)–PCR products from Opdc mutant mice showed that
the mutant allele is transcribed and correctly spliced (data
not shown).
The heterozygous Opdc phenotype is milder than Pax2 loss
of function and is background-dependent
The Pax21Neu loss-of-function mutation results in a significant
degree of lethality of carriers (23). We initially noted that with
Opdc after crossing to C57BL/6J for more than nine gener-
ations, only about two-thirds of the expected number of het-
erozygotes survived to weaning (Table 1) (x2 ¼ 10.7, d.f. ¼
1, P , 0.01). However, this is background strain-dependent.
When we backcrossed the mutation onto a C3H background
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for four or more generations, there was no detectable loss of
heterozygotes (x2 ¼ 0.26, d.f. ¼ 1, 0.9 . P. 0.5), but note
that there is a low incidence of exencephaly (discussed
subsequently). The lethality on the C57BL/6J background
occurs post natally, as the expected numbers of each genotype
are present at embryonic stages in both strains (Table 1). The
heterozygous phenotype for loss of Pax2 function in humans
or mice consistently includes severe kidney defects, which
would account for the loss of carriers on some backgrounds.
In mice heterozygous for a loss-of-function mutation,
kidneys are 60% the size of wild-type, and the number of
nephrons formed is significantly reduced (24,25). In addition,
unilateral kidney agenesis has been reported in 4–6% of these
mice (15,25). We measured kidney weight at E18.5 from het-
erozygous Opdc embryos and their wild-type littermates
(Table 2). There was no significant difference in the kidney
weight, corrected for total embryonic weight, between wild-
type and Opdc heterozygous embryos on a C3H background,
but on the C57BL/6J background, the heterozygous kidneys
were, on average, 71.5% the size of wild-type. The reduced
kidney size was also paralleled by reduced glomeruli
number in mutants on this background (although statistical
significance is marginal), but on a C3H background, there
was no difference in the glomeruli number (Table 3). We
noted unilateral renal agenesis in 1/21 heterozygous embryos
on the C57BL/6J background and 0/13 on the C3H back-
ground.
Homozygous Opdc phenotype
Homozygotes for existing mutant alleles of Pax2 are embryo-
nically lethal or suffer neonatal death, probably due to kidney
agenesis (15,18). Opdc also causes embryonic lethality when
homozygous. One hundred offspring from intercrosses of
Pax2Opdc/+ animals were genotyped at weaning; no homozy-
gotes were detected, whereas 61 were heterozygous and 39
wild-type. To ascertain the causes of lethality and to
examine any other phenotypic effects of the Opdc mutation,
embryos derived from Pax2Opdc/+ intercrosses were recovered
at various development stages and used for morphological and
histological analyses. We find the homozygous phenotypes of
the kidney, ear and eye to be very similar to those described
for existing loss-of-function mutations (15,18,19). Magnetic
resonance imaging (MRI) scans of homozygous embryos at
E15.5 indicated that the kidneys were absent (Fig. 2E–G,
compare with MRI scans from E15.5 heterozygous embryos
in Fig. 2I–K). From the MRI scans, the eye appears mal-
formed in the homozygous mutant (Fig. 2H, compare with
wild-type and heterozygous in Fig. 2D and L). Histological
sections through the eyes of E15.5 homozygotes and heterozy-
gotes showed expansion of the retina down the optic stalk in
both, as described previously for Pax2 null mutants, and the
abnormal phenotype was more severe in homozygotes than
in heterozygotes (3B) (15,19). Scans of the inner ear revealed
severe abnormalities; after 3D rendering, the semi-circular
canals appear grossly dilated and the cochlea is malformed
(Fig. 3A). Similar abnormalities have been reported for
loss-of-function alleles of Pax2 (19).
Pax2 is involved in the specification of the midbrain–
hindbrain boundary and in neural tube closure, although the
severity of the phenotype is affected by the genetic back-
ground (15,20). To assess the effect of the Opdc mutation
on different genetic backgrounds, we crossed it onto C57BL/
6J or onto C3H for at least four generations and intercrossed
Pax2Opdc/+ mice to generate homozygous mutant embryos
and wild-type littermates at E15.5. We find that Opdc
Figure 1. Pax2 is mutated in Opdc mice. (A) Genomic DNA sequence traces
from Pax2 exon 2 from wild-type (WT) and heterozygous mutant (Opdc/+)
mice. The arrow points to the position of the T-to-C transition. (B) Schematic
diagram of the Pax2 paired domain. The black boxes represent the a-helices,
and the arrow points to the position of the isoleucine to threonine mutation
generated by the Opdc mutation in the first a-helix of the paired domain.
(C) The isoleucine mutated in Opdc is located in the first a-helix of the
paired domain and does not directly interact with the DNA-binding site.
The structure of the PAX6 paired domain complexed with DNA (11) is
shown on the left, and the structure of the PAX5 paired domain complexed
with DNA (22) is shown on the right; crystal structures 6PAX and 1K78,
respectively (http://www.pdb.org date last accessed 26/10/2010). The struc-
tures are drawn using the VMD program (55). The DNA-binding sites are
shown in grey, and the paired domains are shown in green with the equivalent
isoleucines to I40 in the Pax2 paired domain indicated by black arrows and
coloured blue with the side chain shown in orange and drawn as scaled van
der Waals spheres with cylinders as bonds. In both cases, the highlighted iso-
leucine is in the first a-helix positioned away from the DNA recognition site in
the hydrophobic pocket with the side chain pointing towards the third a-helix
where the majority of protein–DNA interactions take place.
Human Molecular Genetics, 2011, Vol. 20, No. 2 225
homozygote embryos have exencephaly with variable pene-
trance, depending on the genetic background. On the
C57BL/6J background, 30% (6/20) of the homozygous
mutant embryos showed the phenotype, whereas on the C3H
background, the penetrance increased greatly to 95% (20/
21). There is also a low level of exencephaly seen in heterozy-
gotes, about 2% (1/47) on the C57BL/6J background and 12%
(4/34) on the C3H background. The hindbrain developmental
phenotype of homozygous Pax2 loss-of-function mutants also
varies according to the genetic background. On a largely C3H
background, homozygotes fail to form a cerebellum (15). In
contrast, cerebellar formation is normal on the C57BL/6J
background (20). In contrast to null alleles of Pax2, we
found that the cerebellum was present in Opdc homozygotes
regardless of the genetic background (Fig. 3C).
In conclusion, aspects of the Opdc heterozygous and homo-
zygous phenotypes are less severe than those reported for
loss-of-function alleles, which suggests that the mutant Opdc
Pax2 protein retains some function and that the allele is a
hypomorph.
DNA-binding properties of Pax2Opdc
Structural predictions suggest that the mutant amino acid
found in the Opdc Pax2 paired domain is not involved in
direct DNA contact (Fig. 1C). However, it is possible that
the mutation perturbs the structure of the paired domain.
Therefore, we investigated the effect of the mutation on the
binding of the Pax2 paired domain to target DNA sequences.
We produced and purified recombinant His-tagged paired
domains from wild-type and Opdc mutant Pax2 proteins and
used these in bandshift experiments with a number of known
Pax2 binding sites (Fig. 4E). First, we used the high affinity
Pax2 binding site, Pax2Con (26), as a probe. Both wild-type
and Opdc paired domains formed a complex with Pax2Con
that resulted in a robust gel shift (Fig. 4A). However, when
we used the suboptimal site e5, which is a target site of the
Drosophila prd gene (27), as a probe, the Opdc Pax2 paired
domain did not form a complex, although the wild-type
Pax2 paired domain did (Fig. 4A). This suggested that the
Opdc mutation prevents the binding of the Pax2 paired
domain to suboptimal target sites. To compare the strength
of the binding of the wild-type and mutant Pax2 paired
domains to an optimal binding site, we performed a compe-
tition bandshift using labelled Pax2Con as a probe and
adding increasing amounts of unlabelled Pax2Con as competi-
tor (Fig. 4B). The Opdc paired domain complex was disrupted
at lower concentrations of the Pax2Con competitor compared
with the wild-type complex, indicating that the mutant protein
was bound less tightly than the wild-type (Fig. 4B). When
unlabelled e5 probe was used as competitor, neither the wild-
type nor the mutant Pax2Con–protein complexes were dis-
rupted (data not shown). Thus, although the Opdc mutation
does not abolish the ability of its paired domain to bind to
the strong binding site (Pax2Con), it does reduce the affinity
of the interaction. With less favourable binding sequences
such as e5, the Opdc mutation prevents binding of the
paired domain. Although these results suggest that Opdc is a
hypomorphic mutation, neither of these sequences have been
described in bona fide in vivo Pax2 binding sites. To assess
the effect on the interaction of the Pax2 paired domain with
authentic binding sites, we used binding sites as probes that
have been found in the upstream region of Pax6 (P6), the
upstream region of Pax2 (P2) and in Pax6 retinal enhancer
(Enh) (28) (Fig. 4E). The wild-type Pax2 paired domain
bound to all as expected (Fig. 4C). In contrast, the Opdc
paired domain bound to P2, bound weakly to P6 but could
not bind to Enh (Fig. 4C). We also tested sites Dd and Pc
that have been identified upstream of the Pou3f3 gene
(Fig. 4E) (29). In this case, the Opdc paired domain could
bind to the Dd site, albeit less strongly than wild-type and
bound only weakly to the Pc site (Fig. 4D). These results
demonstrate differential binding of the wild-type and mutant
paired domains to mouse Pax2 targets. Although the Opdc
mutant protein is able to bind to most target DNA sites, the
affinity of binding is variable and reduced at some of the
binding sites. There appears to be a correlation between
the capability of the Opdc paired domain to bind and the simi-
larity of the site to the consensus (Fig. 4E). The e5 and Enh
sites that were not bound by the Opdc paired domain match
least well to the Pax2 consensus binding sequence.
Transcriptional activation by Opdc mutant Pax2
We next investigated the ability of wild-type and mutant Pax2
protein to transactivate transcription in a reporter assay. There
are two major isoforms of the Pax2 protein, which include or
omit 23 amino acids encoded by the alternatively spliced exon
6 (30); these are the long and short isoforms Pax2a and Pax2b
designated P32114-1 and P32114-2, respectively (http://www.
uniprot.org date last accessed 26/10/2010). We introduced the
Opdc mutation into constructs expressing each form,
CMV-Pax2a and CMV-Pax2b (31). We tested the ability of
these to transactivate a luciferase reporter gene downstream
of various Pax2 binding sites by transiently co-transfecting
constructs into NIH-3T3 cells (Fig. 5). We examined the
effect of each wild-type and mutant isoform of the Pax2
protein on a promoter containing five tandem copies of the
Table 1. Mice or embryos wild-type, homozygous or heterozygous for the Opdc mutation on two genetic backgrounds
Background strain Stage Cross ++ Pax2Opdc/+ Pax2Opdc/Opdc P-valuea
C57BL/6J Weaning Pax2Opdc/+ × wild-type 137 88 N/A ,0.01
C3H Weaning Pax2Opdc/+ × wild-type 131 123 N/A .0.5
C57BL/6J Embryo, E15.5 to E18.5 Pax2Opdc/+ × Pax2Opdc/+ 30 63 26 .0.5
C3H Embryo, E15.5 to E17.5 Pax2Opdc/+ × Pax2Opdc/+ 32 49 28 .0.1
aTest for significance using x2 test.
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artificial Pax2 binding site PRS4 (32) cloned upstream of luci-
ferase. Both wild-type proteins strongly activate the luciferase
reporter gene driven by this promoter by 27- and 33-fold,
which is significantly higher when the mutant versions of
the protein were used (Fig. 5A). However, both Opdc
mutant proteins do demonstrate weaker but significant transac-
tivation activity on this promoter, 2.5-fold in the case of Pax2-
aOpdc (t-test, P ¼ 0.023) and 7.8-fold in the case of Pax2bOpdc
(t-test, P ¼ 0.0013) (Fig. 5A). In contrast, when we used two
alternative promoters in this assay derived from the putative in
vivo Pax2 targets, Pou3f3 (29) and RET (25), we find that the
wild-type proteins activate them much less strongly (Pou3f3
2.6- and 3.2-fold and RET 2.1- and 3.5-fold) and that the
Opdc mutant proteins show no significant activation
(Fig. 5B and C).
Transcription of downstream genes in Pax2Opdc/1 mutants
To test the effect of the Opdc mutation in vivo, we examined
the levels of two Pax2 target genes in Pax2Opdc/+ mutant
embryonic kidneys. It has been reported that the transcription
of Ret is reduced in heterozygous Pax2 null kidneys at E18.5
by 47.5-fold relative to the expression in wild-type kidneys
(25). The genes Wt1 and Pax2 are thought to regulate each
other’s expression during kidney development, and in
Pax21Neu/+ kidneys at E19, the expression of Wt1 was reported
to be elevated by 35% relative to its expression level in wild-
type kidneys (23). To determine the level of expression of Ret
and Wt1 in Opdc heterozygous mice, we performed real-time
quantitative RT–PCR analysis using RNA isolated from
E18.5 wild-type and heterozygous Opdc mutant kidneys on
both C3H and C57BL/6 backgrounds. To compare with the
previously reported loss-of-function mutation, we assayed in
parallel the level of Wt1 and Ret mRNA in heterozygous
Pax21Neu mutant kidneys on the C57BL/6 background. In con-
trast to previous reports, we detected no significant change in
the level of expression of either gene in mice heterozygous for
either mutant on either genetic background, although there
was some degree of variation between individual animals of
the same genotype (Fig. 6).
DISCUSSION
The phenotype of mice homozygous and heterozygous for
Opdc is similar to that of loss of function of Pax2, but
some aspects are milder and more sensitive to genetic back-
ground. There are striking differences in the phenotypic con-
sequences of the Opdc mutation on the C57BL/6J and C3H
genetic backgrounds. In homozygous mutant embryos,
although cerebellar development is normal on both genetic
backgrounds (Fig. 3C), we observe a high incidence of exen-
cephaly on the C3H background. On the C57BL/6J back-
ground, the viability of heterozygotes is impaired whereas
on the C3H background, we observe the expected number
of heterozygous mice at weaning. A similar effect on viability
is seen with Krd/+ mice, which carry a 7-cM deletion that
includes the Pax2 gene, although the detrimental effect of
the C57BL/6 background is more severe because after back-
crossing Krd onto C57BL/6 for six generations, no Krd/+ off-
spring were found (33). This probably reflects both the impact
of the C57BL/6 genetic background on viability caused by
loss of one copy of Pax2 and adverse effects on viability
due to haploinsufficiency for the other genes in the deletion
interval.
The mutant Pax2 protein is still able to bind to target DNA
sequences, albeit with reduced affinity, and is still able to
transactivate reporter genes, also with reduced efficiency.
I40, the amino acid altered by the Opdc mutation, is located
in the core of the hydrophobic pocket of the N-terminal subdo-
main of the paired domain with the side chain of the isoleucine
(shown in orange in Fig. 1C), extending towards the third
a-helix which fits into the major groove and contacts the
DNA (9,11). Replacement of the hydrophobic isoleucine
with the polar threonine might pull the third a-helix out of
the major groove and destabilize DNA-protein binding.
However, as the two subdomains do not interact and are struc-
turally independent (8–10), the Opdc mutation would not be
expected to affect interactions between the C-terminal subdo-
main and DNA, and this is what may be mediating the DNA-
binding activity of the Opdc mutant protein. Indeed, there are
alternative splice forms of Pax6 and Pax8, in which the N-
terminal subdomain is disrupted, which can bind DNA recog-
nition sequences solely via the C-terminal subdomain (10,34).
We suggest that the mutant Opdc protein retains some normal
Pax2 function, hence the milder phenotype, and that this
residual function renders the activity of the protein more
labile and more susceptible to the effects of genetic back-
ground.
Although haploinsufficiency for the related gene PAX6
usually causes aniridia in humans (35), missense mutations
in the paired domain have been found to result in variant
Table 2. Kidney mass as fraction of total embryo mass of E18.5 embryos wild-type or heterozygous for the Opdc mutation, in two strains
Background strain Genotype Left kidney, % of total
embryo mass (N)
Right kidney, % of
total embryo mass (N)
Significance left
versus righta
C57BL/6J Wild-type 0.57 (15) 0.52 (15) P ¼ 0.203
C57BL/6J Heterozygous 0.39 (21) 0.38 (21) P ¼ 0.817
Significance wild-type versus heterozygousa P ¼ 0.000337 P ¼ 0.007908
C3H Wild-type 0.42 (11) 0.40 (11) P ¼ 0.790
C3H Heterozygous 0.42 (10) 0.35 (10) P ¼ 0.097
Significance wild-type versus heterozygousa P ¼ 0.970894 P ¼ 0.381662
aTest for significance using t-test.
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phenotypes. The R26G mutation underlies Peters’ anomaly, a
milder anterior segment eye defect than aniridia, probably
because the mutant protein can bind to a subset of target
PAX6 binding sites (36,37). Ectopia pupillae, congenital nys-
tagmus and mild aniridia have been reported to be caused by
missense mutations in the PAX6 paired domain (38,39). Like
Opdc, two of the missense mutations causing mild aniridia
are located in the hydrophobic core of the N-terminal subdo-
main (39). Although missense mutations affecting the equival-
ent isoleucine in PAX6 to I40 in Pax2 have been found in two
human aniridia patients, one being a change to valine and the
other to serine (http://lsdb.hgu.mrc.ac.uk/home.php?select_
db=PAX6 date last accessed 26/10/2010), in both cases the
severity of the disease is not clear (40, G. Wildhardt, unpub-
lished data).
There are undoubtedly genetic background effects on PAX2
mutations in humans. Studies on patients indicate that the
same mutation in PAX2 can result in variable disease,
ranging from severe eye, kidney and cerebellar defects to
kidney disease with no major effect on the eye (2,3,41).
Within one family with a frame-shift mutation in PAX2, the
kidney defects were more variable than the eye abnormalities
in affected individuals (2). In patients with the G76S mutation,
it was noted that the eye phenotype was mild (13) and a case
of isolated renal hypoplasia in a patient with a nonsense
mutation in Pax2 has been reported (42). Interestingly, in a
family segregating dominantly inherited renal hypoplasia
with no ocular abnormalities, a missense mutation, A111T,
located in the C-terminal subdomain of the PAX2 paired
domain was identified as being causative of the disease (43).
Again, the severity of the disease varied greatly between indi-
viduals, ranging from bilateral renal agenesis to no apparent
disease in obligate carriers.
Mouse inbred strains allow genetic background effects to be
investigated more rigorously than in human patients. We have
found that the dominant, partially penetrant, lethality of the
Pax2Opdc mutation seen on C57BL/6J is largely suppressed
on the C3H background. All other analyses of mouse Pax2
mutations have found a degree of dominant lethality; we
suggest that the hypomorphic nature of Opdc means that on
certain backgrounds, the dominant kidney defect is sup-
pressed. It will be interesting to identify the genes responsible
for this suppression. Increased apoptosis during foetal kidney
development has been found in heterozygous mutants (24),
suggesting that strain differences in genes which trigger or
are involved in this pathway might be responsible for the phe-
notypic differences we have observed. There are numerous
examples of mouse strain-specific phenotypic modifiers, for
example, dominant lethality due to loss of function of
Nkx2.5 (44), the severity of various recessive models of poly-
cystic kidney disease (45) or the presence of cataracts in mice
mutant for the vacuolated lens mutation of Gpr161 (46). Rela-
tively few of these modifiers of mutant phenotypes (as
opposed to quantitative trait loci affecting complex genetic
traits) have been mapped, and fewer still have been associated
with identified genes. Matteson et al. (46) identified Foxe3,
which itself results in cataracts when mutant, as the gene
whose strain variation modifies the penetrance of the vacuolar
cataract phenotype of Gpr161.
Genetic and genomic resources currently under develop-
ment will greatly facilitate future identification of genetic
modifiers. The collaborative cross recombinant inbred
strains (47) will enable modifiers of dominant phenotypes to
be relatively easily fine mapped. Furthermore, the genome
sequences of many of the commonly used inbred mouse
strains, including the eight used in the collaborative cross,
are now available, which should allow rapid candidate
gene identification (http://www.sanger.ac.uk/resources/mouse/
genomes/ date last accessed 26/10/2010).
Table 3. Glomeruli counts in wild-type and heterozygous mice in C57BL/6J
(at E18.5) and in C3H (at P0)
Background strain Genotype Average
glomerulus count
Significancea
C57BL/6J WT 13.33
C57BL/6J WT 11
C57BL/6J WT 11.66
C57BL/6J Het 10.66
C57BL/6J Het 9
C57BL/6J Het 8.33 P ¼ 0.065
C3H WT 17
C3H WT 12.5
C3H WT 21.5
C3H WT 19.5
C3H Het 15
C3H Het 13.5
C3H Het 21 P ¼ 0.4
Glomerular density analysis on haematoxylin- and eosin-stained sections was
carried out essentially as described (25).
aSignificance assessed by t-test on total data. Figure 2. Opdc causes renal agenesis and developmental retardation of eyes.
MRI of the kidneys and eyes of E15.5 embryos. (A–C) Transverse and sagittal
sections showing the left and right kidneys (lk and rk) and left and right adre-
nals (la and ra) in a wild-type embryo. (D) Transverse section showing the eye
structures including lens (l), vitreous (v) and retina (r) in a wild-type embryo.
(E–H) Corresponding sections through a Pax2Opdc/Opdc embryo, showing that
the kidneys are absent. The bilateral structure ‘X’ may be an adrenal. The eyes
are poorly developed, with the vitreous not clearly seen in any section. (I–L)
Corresponding sections through a Pax2Opdc/+ embryo which looks normal.
Scale bar ¼ 50 U (1250mm).
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Finally, our finding that on some inbred genetic back-
grounds Pax2Opdc heterozygotes have coloboma defect but
no apparent kidney disease suggests that PAX2 could be a can-
didate in human patients for colobomatous defects alone. A
relatively small number of patients with isolated optic nerve
coloboma or with other eye defects have been reportedly
screened for mutations in PAX2 without success (48), but a
larger screen may be merited.
MATERIALS AND METHODS
Animals
The animal studies described in this paper were carried out
under the guidance issued by the Medical Research Council
in Responsibility in the Use of Animals for Medical Research
(July 1993) and Home Office Project Licence nos PPL60/
2242, PPL60/3124 and PPL60/3785. The Opdc strain has
been submitted to the European Mouse Mutant Archive (http://
www.emmanet.org/ date last accessed 26/10/2010) strain
number EM:01942.
Linkage analysis
PCR products containing informative single nucleotide poly-
morphisms were amplified from genomic DNA extracted
using standard procedures from BALB/c (the ENU-
mutagenized strain), C57BL/6J (the strain used for backcross-
ing) and backcross progeny and sequenced as described below.
Mutational analysis of Pax2
The exons and the immediate flanking sequences of Pax2 were
amplified from Opdc, BALB/c, C3H and C57BL/6J genomic
DNA using intronic primers that were also used for subsequent
sequence analysis. PCR products were purified using a Milli-
pore Multi-screen PCR 96-well filtration system on a
Biomek 2000 robotic platform and sequenced directly using
Big DyeTM terminator cycle sequencing. Sequences were ana-
lysed using the SequencherTM program.
Transcription reporter assays
Transfections were carried out using a MicroPorator MP-100,
following the manufacturer’s protocol (Labtech International,
Ringmer, East Sussex, UK). To correct for transfection effi-
ciency and viability, 2.5 ng of renilla reporter vector was
also transfected. The day following transfection, luciferase
assays were carried out using the Dual-luciferase reporter
assay system (E1910, Promega UK, Southampton, Hampshire,
UK), and readings were normalized using the renilla reporter.
Each experiment was carried out in triplicate.
Constructs and recombinant protein production
The Opdc mutation was introduced into CMV-Pax2a and
CMV-Pax2b [(31), a gift of G. Dressler] by replacing the
FseI to NheI fragment containing the site of the Opdc mutation
with the equivalent fragment from pHCMV-Pax2 [(49), a gift
of P. Gruss] that had the Opdc mutation introduced into it
using the QuikChange Site-Directed Mutagenesis Kit (Strata-
gene, Agilent Technologies, Inc., Santa Clara, CA). To make
the plasmid PRS4Luc, the PRS4 binding site was amplified
from pRS4CAT [(32), a gift of G. Dressler] using oligonucleo-
tides 5′-GTTTTCCCAGTCACGACGTT-3′ and 5′-GGCCTG
CAGTGCTCTGCCTTTTATGCCCAAGCTAGAGTCGAGA
TATCTAGAGC-3′ and cloned into pGEMTEasy (Promega).
The resulting plasmid was digested with SalI and PstI and
the fragment containing PRS4 isolated and cloned into the
SalI and PstI sites of Pax6enh/Luc-S [modification of
Figure 3. Opdc causes inner ear and eye defects but does not affect cerebellar
development. (A) The images show the endolymphatic-filled membranous
labyrinth within the cochlea and semi-circular canals from wild-type and
homozygous Opdc mutants. The cochlea of the homozygous Opdc mutant is
highly malformed having a broad hook shape, whereas the semi-circular
canals appear comparatively normal in shape compared with that of the wild-
type. (B) Transverse sections through embryonic eyes at E15.5. In Pax2Opdc/+,
the retina extends down the optic stalk and this is more pronounced in the
Pax2Opdc/Opdc embryo (arrowheads). (C) The Opdc mutation does not affect
cerebellar development. Transverse sections through the cerebellum at
E15.5. On both the C3H and the C57BL/6 backgrounds, the cerebellum devel-
ops normally, compare Pax2Opdc/Opdc and Pax2Opdc/+ embryos. Scale bar ¼
100 mm.
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plasmid pluc-S (50, a gift of D.J. Kleinjan)] with the result that
PRS4 is placed upstream of a luciferase reporter. To make the
Pou3f3prom reporter plasmid, the following oligonucleotides,
5′-GATCTGAATTCGATCGGGCCCA-3′ and 5′-AGCTTGG
GCCCGATCGAATTCA-3′, were annealed and cloned into
the BglII and HindIII sites of the pGL3-Basic vector polylin-
ker (Promega) to introduce EcoRI and PspOMI restriction
sites and to create vector pGL3-BasicLink. The 3.2 kb
BglII–NotI fragment of the Pou3f3 gene promoter from bac-
terial artificial chromosome clone RP23-347M3 that contains
the Dd and Pc binding sites was cloned into the BglII and
PspOM1 sites of pGL3-BasicLink to make Pou3f3prom. All
constructs were verified by sequencing.
To produce histidine-tagged (His-tagged) proteins contain-
ing the wild-type and Opdc Pax2 paired domains, recombinant
plasmids were made in two steps. The 3′ end of the paired
domain coding sequence was amplified by PCR from adult
Opdc heterozygous kidney cDNA using primers 5′-GATA
TGCACTGCAAAGCAGACC-3′ and 5′-GCGGATCCGGA
TGATCCTGTTGATG-3′, which introduce a BamHI site at
the 3′ end. This was digested with NcoI and BamHI, cloned
into the NcoI and BamHI sites of pET6H (51) and the resulting
plasmid pET6HPax2NB verified by sequencing. The 5′ end of
the Pax2 coding sequence was amplified by PCR from adult
Opdc heterozygous kidney cDNA using primer pairs
5′-CCTCTGCCTCCCCATGGAT-3′ and 5′-CTTGATGCTG
Figure 4. The Opdc mutation impairs the binding of the Pax2 paired domain to target sites. (A) Bandshift analysis using either the consensus Pax2 binding site
Pax2Con (26) (left panel) or a less favourable probe e5 (27) (right panel) with no protein (–), increasing amounts of recombinant Pax2 paired domain with either
wild-type (WT) or the Opdc mutation (Opdc) as indicated by the triangle. Both WT and Opdc paired domains could bind to Pax2Con, but only the WT bound to
e5. (B) Bandshift analysis using the high affinity probe Pax2Con. In the first lane, no protein was added (–); in lanes 2–6, recombinant WT Pax2 paired domain
was added and in lanes 7–11, recombinant Opdc Pax2 paired domain (Opdc) was added. Increasing amounts of unlabelled Pax2Con were added as competitor as
indicated by the triangle in lanes 3–6 and lanes 8–11. The DNA–Opdc protein complex was disrupted more easily than the DNA–WT protein complex.
(C) Bandshift analysis using Pax2Con (26), Pax2 binding sites from the Pax2 gene promoter, P6 and P2, and a Pax2 binding site from the Pax6 retinal enhancer
region, Enh (28). Reactions with no protein (–), WT Pax2 paired domain or Opdc Pax2 paired domain (O) are shown. The WT Pax2 paired domain bound to all
sites, whereas the Opdc Pax2 paired domain bound to the P2 binding site, bound very weakly to the P6 binding site and did not bind to the Enh binding site.
(D) Bandshift analysis using either the Dd binding site (left panel) or the Pc binding site (right panel) from the Pou3f3 gene promoter (29) with increasing
amounts of recombinant Pax2 paired domain either WT or containing the Opdc mutation (Opdc) as indicated by the triangle. In the first lane of each panel
no protein was added (–). The WT Pax2 paired domain bound to both sites, and although Opdc Pax2 paired domain could bind to both binding sites, it
bound slightly less well than the WT to Dd and only weakly to Pc. (E) Sequences of the DNA probes used. At the top is the Pax2 consensus binding sequence
(50), alternative nucleotides are given in positions in which the occurrence of the minor nucleotide is greater than 30%. Below this, the binding sequences used
are in order of agreement with the consensus sequence. In each binding site, uppercase indicates nucleotides that are found in the consensus sequence and the
degree of binding of each to the Opdc paired domain is in parentheses, + indicating good binding. The e5 and Enh probes that did not bind to the Opdc paired
domain conform least well to the consensus sequence. R ¼ A or G, N ¼ A, G, C or T, S ¼ G or C, W ¼ A or T, K ¼ T or G and M ¼ C or A.
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CCAGTCTCGT-3′ that introduce an NcoI site adjacent to the
start codon. This was digested with NcoI and cloned into the
NcoI site of pET6HPax2NB. By restriction digest mapping
and sequencing clones were identified, which contained
either the wild-type (pET6HWTPD) or Opdc
(pET6HOpdcPD) Pax2 sequence encoding amino acids
1–139 fused downstream of a 6× His tag encoded by the
vector. Recombinant proteins were expressed in the Escheri-
chia coli strain BL21 (DE3) pLysS essentially as described
(52) and purified using Ni-NTA Agarose (Qiagen, Crawley,
West Sussex, UK) following standard protocols. Purified pro-
teins were analysed by sodium dodecyl sulphate–polyacryla-
mide gel electrophoresis to assess yield and purity and equal
amounts of wild-type and mutant proteins were used in band-
shift experiments.
Bandshift analysis
Probe sequences are shown in Figure 4E. For each DNA probe
tested, double-stranded oligonucleotides with three or four
base 5′ single-stranded extensions were either end-labelled
by filling in the overhangs using radiolabelled nucleotides
Figure 5. The Opdc mutation impairs Pax2 function. Mouse NIH 3T3 fibroblast
cells were transiently transfected with (A) 400 ng of the plasmid PRS4Luc that
contain five copies of the PRS4 binding site upstream of a luciferase reporter,
(B) 400 ng of pGL3-Ret680 that contains a 680 bp fragment of the c-RET promo-
ter sequence driving a luciferase reporter (25) and (C) 400 ng of
pGL3-Pou3f3prom that contains a 3.2 kb BglII–NotI fragment from the
Pou3f3 gene promoter upstream of a luciferase reporter. For each, either no
vector (–) or 400 ng of the following was co-transfected: CMV vector (CMV),
CMV-Pax2a (Pax2a), CMV-Pax2aOpdc (Pax2aOpdc), CMV-Pax2b (Pax2b) or
CMV-Pax2bOpdc (Pax2aOpdc). Each experiment was performed in triplicate,
and mean firefly luciferase expression normalized to control renilla luciferase
expression is shown + standard error. For each reporter, both Pax2a and Pax2b
elicit robust induction of luciferase expression that is significantly reduced by
theOpdcmutation (t-test; ∗P, 0.05, ∗∗P ≤ 0.01, ∗∗∗P, 0.0001). It is important
to note that the activation of expression relative to that seen with the CMV by the
Pax2 construct is the greatest with the PRS4 reporter shown in (A). For the
RET680 and Pou3f3 reporter constructs shown in (B) and (C), there is some acti-
vation observed with the CMV construct and the relative increase in expression is
much less when the wild-type CMV-Pax2 constructs were used.
Figure 6. Ret and Wt1 transcription levels are not significantly reduced in
Opdc/+ and 1Neu/+ E18.5 kidneys. Ret (A) and Wt1 (B) RNA levels from
wild-type and Opdc/+ E18.5 embryo littermates on the C57BL/6 and C3H
backgrounds and wild-type and 1Neu/+ E18.5 littermates on the C57BL/6
background. Mean values and standard deviations of three independent quan-
titative RT–PCR reactions are shown. The expression level of one wild-type
sample from the Opdc line was designated as a calibrator and set to one
(indicted by an asterisk) and the relative expression of other samples to this
is shown.
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and Klenow polymerase (Pax2Con, e5, P2, P6 and Enh) or
DIG-labelled using terminal transferase and DIG-11-dUTP,
following the manufacturer’s instructions (Promega) (Dd
and Pc). Bandshift analysis was carried out essentially as
described (26). His-tagged paired domain proteins were
incubated in 30 ml reactions on ice containing 10 mM
HEPES (pH 7.9), 30 mM KCl, 20% glycerol, 1 mM EDTA,
1 mM b-mercaptoethanol, 250 mg/ml poly(dI.dC), 2.5 mg/ml
bovine serum albumin and either 10 000–16 000 cpm (8 ×
107–1.5 × 08 cpm/mg) radiolabelled DNA probe or 30 fmol
DIG-labelled DNA probe for 30 min. Protein–DNA com-
plexes were resolved by electrophoresing on pre-cooled 6%
polyacrylamide gels in 0.5 × Tris-borate-EDTA buffer for
90 min at 240 V at 48C. If using radiolabelled probes, the
gels were dried onto DE81 paper (Whatman, GE Healthcare
Life Sciences, Little Chalfont, Buckinghamshire, UK) and
subjected to autoradiography. If using DIG-labelled probes,
the gels were transferred to Hybond-N+ (GE Healthcare
Life Sciences), processed according to manufacturer’s
protocol (Promega) and then subjected to autoradiography.
Magnetic resonance imaging
Pregnant mice were sacrificed by cervical dislocation at E14.5
or E15.5. Embryos were dissected and fixed for 7 days in 4%
paraformaldehyde and 2 mM Gd-DTPA (Magnevist, Schering)
in phosphate-buffered saline (PBS) at 48C. Multi-embryo MRI
was performed as described earlier (53) and the image files
analysed using Amira software (TGS Europe, Merignas,
France). For the 3D reconstruction of the inner ear, 3D visual-
ization software was used to view the image data stacks.
Manual segmentation and orthoslice tools were used to
correct voxel size, view in transverse section, crop the data
area and then paint the endolymphatic-filled membranous
spaces of the cochlea and semi-circular canals.
Real-time quantitative RT–PCR
RNA was extracted from E18.5 kidneys using the RNeasy kit
(Qiagen), and first strand cDNA was prepared using
oligo-p(dT)15 primers and the 1st Strand cDNA Synthesis
Kit for RT–PCR (AMV) (Roche Diagnostics) using standard
conditions. Quantitative RT–PCR analysis was performed
using a Lightcyclerw 480 Instrument (Roche Diagnostics
Ltd, Burgess Hill, West Sussex, UK), following the manufac-
turer’s instructions; 10 ml reactions containing 2 ml 1021
dilution of cDNA, 5 ml 2× Lightcycler 480 Probes Master
(Roche Diagnostics Ltd), 0.1 mM UPL probe and 0.5 mM of
each primer were done in 384-well white plates. Assays
were designed using the Probefinder software available at
the Universal ProbeLibrary Assay Design Centre (http://qp
cr.probefinder.com/roche3.html date last accessed 26/10/
2010) (Roche Diagnostics Ltd); information about the
primers and UPL probes used is available upon request. Reac-
tions were incubated at 958C for 10 min, then 55 cycles of
958C for 10 s, 608C for 30 s followed by a final incubation
at 408C for 30 s. Serial dilutions of wild-type cDNA were
used to generate standard curves of each gene tested. Each
assay was done in triplicate, and Ret and Wt1 levels were
quantified and normalized against Pgk1 levels using the
second derivative maximum method using the advanced rela-
tive quantification module of the Lightcyclerw 480 software
release 1.5.0. Essentially the same result was obtained using
Gapdh as the reference gene. Both Pgk1 and Gapdh have
been validated as suitable reference genes for quantitative
RT–PCR analysis of renal gene expression (54).
Embryo histology
After dissection, embryos were photographed and fixed over-
night in 4% paraformaldehyde in PBS at 48C. A small part
of the tail was used for genotyping. After washing in PBS,
they were dehydrated by immersion in a series of increasing
concentrations of alcohol, embedded in paraffin wax, sec-
tioned and stained with haematoxylin and eosin. Slides were
viewed on a Leica MZFLIII fluorescence stereo microscope
fitted with a Coolsnap colour camera (Roper Scientific,
Tucson, AZ, USA). Image capture was controlled by
in-house scripting of IPLab Spectrum (Scanalytics, Fairfax,
VA, USA).
Statistical analysis
Values were expressed as mean+ standard deviation. A two-
tailed unpaired Student’s t-test was used for statistical analy-
sis; P, 0.05 was considered significant.
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